Needham & Company
-
Ionis Pharmaceuticals to present at upcoming investor conferences
-
Ionis Pharmaceuticals (IONS) PT Raised to $87 at Needham & Company
-
Ionis Pharmaceuticals to Present at Upcoming Investor Conferences
-
Akcea Therapeutics to Present at Upcoming Investor Conferences
-
Akcea Therapeutics to Present at Upcoming Investor Conferences
-
Ionis Pharmaceuticals to Present at Upcoming Investor Conferences
-
Buy Ionis Pharmaceuticals (IONS) on Growth Concerns Weakness - Needham & Company
-
Ionis Pharma (IONS): Expert Call Optimistic Despite Safety Profile Concerns - Needham
-
Ionis Pharmaceuticals to Present at Needham Healthcare Conference
-
Needham & Company Reiterates Buy Rating and $64 PT on Ionis Pharma (IONS); 'Market Overreacting'
-
Ionis Pharma (IONS): Takeaways From FCS Expert Call - Needham
-
Needham & Company Reiterates Buy Rating and $64 PT on Ionis Pharmaceuticals (IONS); 'Sustainable Profitability by 2018'
-
Needham & Company Weighs in on Ionis Pharmaceuticals (IONS) After Pipeline Update
-
Needham & Company Reiterates Buy on Ionis Pharmaceuticals (IONS) Following FDA Approval
-
Ionis Pharmaceuticals (IONS) PT Raised to $64 at Needham & Company as ENDEAR Study Halted Early for Efficacy
-
Streetinsider.com's Hot Lunchtime Reads 7/14: (AMZN) (STMP) (IONS) (LN) (MON)
-
Ionis Pharma (IONS): Reiterating Buy After R&D Day - Needham
-
Streetinsider.com's Hot Lunchtime Reads 7/7: (TSLA) (CMG) (MBI) (IONS)
-
Needham & Company Reiterates Buy on Ionis Pharma (IONS) Following TTR Program Updates
-
Needham & Company Remains Positive on Ionis Pharmaceuticals (IONS) But Sees Risk of Continued Volatility
-
Needham & Company Cut PT, But Keeps 'Buy' on Ionis Pharmaceuticals (IONS) Amid Update
-
Akcea Therapeutics to Present at 15th Annual Needham Healthcare Conference
-
Ionis Pharmaceuticals to Present at Upcoming Investor Conferences